Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
GlaxoSmithKline ( (GSK) ) has issued an update.
GSK announced that the US FDA has approved Penmenvy, a 5-in-1 meningococcal vaccine, for use in individuals aged 10 to 25. This vaccine combines components from GSK’s Bexsero and Menveo vaccines, offering protection against five major serogroups of Neisseria meningitidis. The approval is backed by positive phase III trial results involving over 4,800 participants. The vaccine is expected to simplify meningococcal vaccination delivery and increase protection rates among US adolescents and young adults, a group at high risk for invasive meningococcal disease (IMD). This approval reinforces GSK’s position as a leader in meningococcal vaccinations and addresses a significant public health need.
More about GlaxoSmithKline
GSK, or GlaxoSmithKline, is a global biopharmaceutical company that focuses on uniting science, technology, and talent to advance disease prevention and treatment. The company is renowned for its contributions in the development of vaccines and medicines, particularly in the field of meningococcal disease prevention.
YTD Price Performance: 6.54%
Average Trading Volume: 4,491,679
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $73.04B
Find detailed analytics on GSK stock on TipRanks’ Stock Analysis page.
